No Good Reason to Buy Now<br />By Rev Shark<br />RealMoney.com Contributor<br />3/6/2008 8:32 AM EST <br /><br />"The problem is not that there are problems. The problem is expecting otherwise and thinking that having problems is a problem." --Theodore I. Rubin <br /><br />The market is struggling again this morning as margin calls hit Thornburg Mortgage (TMA) and creditors move to seize pledged assets. What is particularly troublesome about this development is that this is a mainstream lender that focused on high-quality jumbo mortgages and not the subprime instruments we have heard so much about. <br /><br />In addition, there are a number of articles this morning about how illiquidity is infecting a number of other debt markets such as intrabank lending. The underlying problem is that we still have little guidance as to how bad the problem will ultimately be, especially if housing prices continue to decline. <br /><br />On the wires, we even have Boston Fed Member Rosengren saying that credit problems are now starting to spill-over to "Main Street." <br /><br />There is no question the economic picture is a gloomy one as the credit markets struggle to come to grips with a host of problems. Some market players keep hoping that the Fed will somehow wave its magic wand and cure these issues, but it appears the market simply has to work through these problems on its own. It is going to take time and it is a mistake to be impatient and to start looking for the market to suddenly improve when we are still trying to fully price in the extent of the debt market issues. <br /><br />We have a soft start on the way this morning as there is little news to drive buyers. Retail reports are coming in and Wal-Mart (WMT) actually has good numbers. Oil continues its rise and with a host of commodities hitting record highs it is going to be tough to argue that inflation is "well anchored." <br /><br />Tomorrow is a very important jobs report and I expect that the market will stay pinned down today as it awaits that news. The only real reason to buy at the moment is that we are slightly oversold on a technical basis. On the other hand, with so little positive news on the wires it is going to be tough for the bulls to get much traction as oversold conditions are slowly worked off. <br /><br />At this juncture I see little reason to do anything other than some short-term trading. The market is showing few signs of forming a solid low and it is clearly going to take a while before things will be healthy enough to generate much upside momentum. The opportunities will come to make money with some longer-term plays, but it is still far too early to be thinking that way. <br />--------------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance/same store sales: UFPT +19.7%, SMSI +18.4%, CHIP +17.5%, DXPE +9.9%, FLOW +8.8%, BBI +8.6%, MATK +7.5%, SNUS +7.5%, OWW +7.4%, CMTL +6.8%, SONS +6.2%, URBN +6.0%, LVB +5.7%, ACUR +5.4%, SMRT +5.0%, PSUN +4.9%, HRB +4.4%, FINL +4.1%, HRS +4.1%, CTR +3.9%, TIVO +3.8%, AUO +2.6%, RAD +2.5%, MELI +2.5%, SHMR +2.5%, JWN +2.2%, ADCT +1.8%, PLCE +1.7%, ROST +1.6%, WMT +1.3%, ANIK +1.3%... Select gold and mining stocks showing strength, despite lower spot prices, with reports that South Africa will raise mines' power supply to 95%: GFI + 3.0% , HMY + 3.0% , BHP + 2.4% , RTP + 1.8% , LMC + 1.7% , GOLD + 1.2%... Other news: EXAS +65.1% (says updated screening guidelines of the American Cancer Society include new DNA technology for detecting colorectal cancer), OPTM +43.1% (still checking), EPCT +20.7% (earns milestone payment due to progress in Phase II trial for Azixa in melanoma metastases), TSRA +11.8% (addresses "mischaracterizations of patent validity and legal process"; Cowen makes positive comments), THRX +11.1% (FDA accepts for review THRX's complete response to approvable letter for Telavancin for the treatment of complicated skin and skin structure infections), PBT +4.6% (Cramer makes positive comments on MadMoney), RHD +4.1% (modestly rebounding after making new 52 week low yesterday), SHPGY +1.6% (still checking), INAP +1.5% (SoftLayer signs 5-year $40 mln contract with Internap to expand on-demand hosting platform across the United States), BHI +1.3% (discloses it starts a $500 mln commercial paper program), MOT +1.1% (Carl Icahn discloses increased stake of 6.3%, up from 5.0% prior stake), TASR +1.1% (receives two law enforcement orders; Suffolk County Police Dept and North Dakota Highway Patrol purchase TASER devices )... Analyst upgrades: MDR +3.8% (upgraded to Buy at Citigroup), ORCL +2.2% (upgraded to Buy at Merrill), FLR +1.9% (upgraded to Buy at Citigroup), DISH +1.3% (upgraded to Neutral at Credit Suisse), ENDP +1.0% (upgraded to Buy at Roth Capital).<br /><br />Allapoole avanevad:<br /><br />In reaction to weak earnings/guidance/same store sales: UDRL -22.4%, CWTR -20.4% (also downgraded to Hold at Roth Capital), WINS -14.2% (also downgraded to Hold at Roth Capital), ZUMZ -14.0% (also downgraded to Neutral from Buy at Piper Jaffray), MR -9.8%, AEO -8.4%, RWC -8.3%, OWW -7.7%, USMO -7.2%, AOB -7.1%, MWRK -6.5%, PETM -6.4%, RWT -6.4%, JCP -4.4%, GPS -4.2%, FCEL -4.0%, STEC -4.0%, BRLI -2.3%, EXC -1.8%... Select mortgage stocks showing continued weakness following TMA news related to margin calls: TMA -52.1% (discloses receipt of default notice from JP Morgan after TMA failed to meet a $28 mln margin call), CMO -14.7% (removed from Best ideas List at Keefe Bruyette), NLY -14.4% (removed from Best ideas List at Keefe Bruyette), RAS -12.2%, IMB -7.9%, ABK -7.4% (continued weakness from yesterday's huge ~23% decline), FRE -4.3%, FNM -4.2%... Select financial names showing continued weakness: MER -6.4% (discontinues First Franklin Mortgage Origination; amended the terms of its Exchange Liquid Yield Option Notes due 2032; estimates cut at Keefe Bruyette), LEH -3.8% (estimates cut at Keefe Bruyette), MS -2.6% (estimates cut at Keefe Bruyette), BSC -2.3% (estimates cut at Keefe Bruyette), WM -2.3%, C -1.9% (made no approach for capital, Dubai says - Reuters.com), WFC -1.8%, GS -1.7% (estimates cut at Keefe Bruyette), BAC -1.5%, UBS -1.2% (shares sink on Alt-A writedown talk - Reuters)... Other news: CIM -12.6% (still checking), MGI -6.8% (showing continued weakness following yesterday's huge decline), CSE -2.9% (still checking), TMS -2.4% (showing continued weakness), LCAPA -1.8% (still checking), HNSN -1.6% (files a $75 mln common stock shelf offering in an S-3), TOT -1.4% (still checking)... Analyst downgrades: MFA -19.4% (downgraded to Mkt Perform at Keefe Bruyette), ANH -15.4% (downgraded to Mkt Perform at Keefe Bruyette), SKS -4.9% (downgraded to Neutral at BofA), BDN -3.8% (downgraded to Underperform at RBC), DRE -2.4% (downgraded to Underperform at RBC).